Topotecan eye injection for retinal detachment with scarring
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests an experimental drug called topotecan, given as an injection directly into the eye during surgery, to see if it safely helps prevent scar tissue from pulling the retina out of place again. It is for people having surgery for retinal detachment with severe scarring or injury.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You have a retinal detachment with severe scar tissue (PVR) or from an eye injury
- You are already scheduled for surgery to repair the detachment
- You are not pregnant (women of childbearing age will have a pregnancy test)
- You do not have other serious eye conditions like diabetic retinopathy or chronic inflammation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an injection of a drug called topotecan, given during or right after eye surgery for retinal detachment, can help prevent or treat a condition called proliferative vitreoretinopathy (PVR) that can cause the retina to detach again. If you're having surgery for a retinal detachment, this trial might help reduce the risk of needing more surgeries.
This trial studies a surgical technique that may improve vision in people with a detached retina and scar tissue inside the eye. It asks whether removing a thin layer from the retina during surgery helps the retina heal better.
This Phase 2 trial tests an injection of topotecan into the eye after surgery for retinal detachment that keeps coming back due to scar tissue (proliferative vitreoretinopathy). It may help improve how the retina heals after difficult, repeat operations when vision is usually very guarded.
This trial tests a new way to deliver the chemotherapy drug topotecan directly to the eye (via a small patch placed on the eye surface) for children with retinoblastoma that either needs eye removal or has come back after standard treatment. It aims to see if this approach can help save the eye and vision.
This trial tests a high dose of a chemotherapy drug called topotecan given directly into the eye (intravitreal injection) for children with retinoblastoma that has come back or not responded to treatment and has seeds floating in the vitreous. The goal is to save the eye when removal is the only other option.
This trial studies whether a combination chemotherapy treatment (topotecan plus melphalan) can help children with retinoblastoma while keeping the eye when possible. It’s a Phase 3 study, meaning it’s testing effectiveness in a larger group of patients.
Hear when a new Proliferative Vitreoretinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.